Evidence map›Paper›PMID 35300888›Full record

Trial reportEuropean urology2022

Thulium Fibre Laser versus Holmium:YAG for Ureteroscopic Lithotripsy: Outcomes from a Prospective Randomised Clinical Trial.

Øyvind Ulvik, Mathias Sørstrand Æsøy, Patrick Juliebø-Jones, Peder Gjengstø, Christian Beisland

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in European urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07741084 (FANS vs Sheathless URS Lithotripsy - a Prospective, Randomised Clinical Trial), which is not on this map. Cited by 108 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
108citing papers in PubMed, 9 pooled it
27.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07741084 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

FANS vs Sheathless URS Lithotripsy - a Prospective, Randomised Clinical Trial

TypeinterventionalSponsorHaukeland University HospitalRan2026 to 2027Enrolled225ConditionsRenal StonesArmsSheathless URS, FANS, low power, FANS, high power
3 · Its place in the literature

Who cites it

108 citing papers in PubMed, 9 syntheses or guidelines pooled it, 190 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. Article
  16. Article
  17. Adoption of thulium fiber laser for lithotripsy A scoping review and bibliometric analysis.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2026
    Review
  18. Article
  19. Article
  20. Article

48 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Øyvind UlvikDepartment of Urology, Helse Bergen HF, Haukeland University Hospital, Bergen, Norway; Department of Clinical Medicine, University of Bergen, Bergen, Norway. Electronic address: doc.ulvik@online.no.
Mathias Sørstrand ÆsøyDepartment of Urology, Helse Bergen HF, Haukeland University Hospital, Bergen, Norway.
Patrick Juliebø-JonesDepartment of Urology, Helse Bergen HF, Haukeland University Hospital, Bergen, Norway; Department of Clinical Medicine, University of Bergen, Bergen, Norway.
Peder GjengstøDepartment of Urology, Helse Bergen HF, Haukeland University Hospital, Bergen, Norway.
Christian BeislandDepartment of Urology, Helse Bergen HF, Haukeland University Hospital, Bergen, Norway; Department of Clinical Medicine, University of Bergen, Bergen, Norway.
Haukeland University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHolmium:yttrium-aluminium-garnet (Ho:YAG) laser is the gold standard for ureterorenoscopic (URS) lithotripsy. Thulium fibre laser (TFL) has recently been introduced as a new technology and may challenge Ho:YAG as the preferred laser owing to favourable properties as demonstrated in preclinical studies.

objectiveTo evaluate and compare outcomes after URS lithotripsy with Ho:YAG and TFL. DESIGN, SETTING, AND

participantsIn a prospective randomised trial, patients aged ≥18 yr with ureteral and/or renal stones (≥5 mm) scheduled to undergo day-case URS lithotripsy were invited to participate. In total, 120 consecutively admitted patients with signed consent were included for randomisation.

interventionURS lithotripsy with Ho:YAG or TFL. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome was the stone-free rate (SFR) assessed on noncontrast computed tomography at 3-mo follow-up. Secondary outcomes were the operative time and complications. Outcomes were compared between the groups using the t test and χ RESULTS AND LIMITATIONS: After a single session, the SFR was 67% in the Ho:YAG group and 92% in the TFL group, p = 0.001. For ureteral stones, the SFR was 100% in both groups, and for renal stones; 49% (Ho:YAG) and 86% (TFL), p = 0.001. Operative time was shorter using TFL (49 min) compared to Ho:YAG (57 min), p = 0.008. Bleeding that impaired the endoscopic view was the most frequent intraoperative adverse event and occurred in 13 patients (22%) in the Ho:YAG group and three (5%) in the TFL group, p = 0.014.

conclusionsIn this study, significantly more patients with renal stones achieved stone-free status and fewer experienced intraoperative complications using TFL compared to Ho:YAG. TFL is the emerging laser of choice for stone lithotripsy. PATIENT SUMMARY: We compared outcomes after ureterorenoscopic treatment of kidney and ureteral stones using two different lasers. Our results show that the new thulium fibre laser technology is superior to the current standard laser (holmium:YAG) in clearing kidney stones and reducing operative complications.

Indexed as

Kidney CalculiLasers, Solid-StateLithotripsyLithotripsy, LaserUreteral CalculiHolmiumHumansProspective StudiesThuliumUreteroscopyHolmiumThuliumComplicationsHolmium:YAG laserRandomised trialStone-free rateThulium fibre laserUreteroscopy

Identifiers

PMID35300888
OpenAlexW4220694180

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.